Klotho Neurosciences, Inc. financial data

Symbol
KLTO, KLTOW on Nasdaq
Location
1115 Broadway, 12 Th Floor, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 459 % +2288%
Debt-to-equity 17.7 % -99.1%
Return On Equity -202 % +89.9%
Return On Assets -171 % -180%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 72.5M shares +321%
Common Stock, Shares, Outstanding 70.3M shares +254%
Entity Public Float 13.6M USD -76%
Common Stock, Value, Issued 7.03K USD +254%
Weighted Average Number of Shares Outstanding, Basic 59.4M shares +256%
Weighted Average Number of Shares Outstanding, Diluted 59.4M shares +256%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 510K USD
General and Administrative Expense 991K USD +344%
Operating Income (Loss) -6.93M USD -78.9%
Nonoperating Income (Expense) -4.36M USD -1078%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -11.3M USD -96.1%
Income Tax Expense (Benefit) 484K USD -80.8%
Net Income (Loss) Attributable to Parent -11.3M USD -168%
Earnings Per Share, Basic 0 USD/shares +72.2%
Earnings Per Share, Diluted 0 USD/shares +72.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.3M USD +14243%
Assets, Current 7.77M USD +4927%
Intangible Assets, Net (Excluding Goodwill) 2.31M USD
Other Assets, Noncurrent 2.31M USD
Assets 10.1M USD +309%
Accounts Payable, Current 34.9K USD -87.1%
Accrued Liabilities, Current 58K USD -89.7%
Liabilities, Current 92.9K USD -90.5%
Deferred Income Tax Liabilities, Net 18.1K USD
Liabilities 146K USD -85.5%
Retained Earnings (Accumulated Deficit) -19.8M USD -133%
Stockholders' Equity Attributable to Parent 9.93M USD +580%
Liabilities and Equity 10.1M USD +309%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.55M USD -6970%
Net Cash Provided by (Used in) Financing Activities 2.06M USD +1075%
Net Cash Provided by (Used in) Investing Activities -123K USD +65.7%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 70.3M shares +254%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -223K USD -13079%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.35M USD +14338%
Deferred Tax Assets, Valuation Allowance 3.02M USD +175%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 3.02M USD +175%
Deferred Income Tax Expense (Benefit) 94.8K USD
Deferred Tax Assets, Operating Loss Carryforwards 2.39M USD +118%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Additional Paid in Capital 29.7M USD +208%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.91M USD -67.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%